​​​​​​​Alumis cuts IPO size, but nets $250M for immune drug work

Immune drug developer Alumis has raised $210 million in one of the biotechnology sector’s largest initial public offerings this year.

Still, the IPO announced Thursday comes in below projections Alumis set earlier this week.